Related Experiment Video

Updated: May 1, 2026

Kinetic Screening of Nuclease Activity using Nucleic Acid Probes
06:52

Kinetic Screening of Nuclease Activity using Nucleic Acid Probes

Published on: November 1, 2019

8.4K

Staphylococcal nuclease and tudor domain-containing protein 1: An emerging therapeutic target in cancer (Review)

Santosh Kumar Rai1, Mohd Imran Khan1, Rakesh Kumar1

  • 1New Drug Discovery Research, Mankind Research Centre Unit-1, Mankind Pharma Limited, Gurugram, Haryana 122051, India.

Molecular and Clinical Oncology
|August 4, 2025
PubMed

Insights

Staphylococcal nuclease and tudor domain-containing protein 1 (SND1) is an oncoprotein driving cancer progression. Targeting SND1

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Staphylococcal nuclease and tudor domain-containing protein 1 (SND1) is an oncoprotein overexpressed in numerous cancers.
  • SND1 plays a critical role in tumor development by interacting with RNA and proteins, including Metadherin (MTDH).

Purpose of the Study:

  • To review the oncogenic functions of SND1.
  • To investigate therapeutic strategies targeting SND1 for cancer treatment.

Main Methods:

  • Literature review of studies on SND1's role in cancer.
  • Analysis of SND1's interactions with RNA and MTDH.
  • Evaluation of therapeutic approaches targeting SND1.

Main Results:

  • SND1 promotes tumor initiation, metastasis, and immune evasion through its nuclease activity and MTDH interaction.
  • Small RNAs bound to SND1 mediate RNA interference, silencing tumor suppressor genes.

Conclusions:

  • SND1 is a crucial therapeutic target in various cancers.
  • Inhibiting SND1's nuclease activity or its interaction with MTDH are promising strategies for cancer therapy.
Keywords:
RNA-induced silencing compleximmune evasionmetadherinmetastasisstaphylococcal nuclease and tudor domain-containing protein 1

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.3K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

642

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.7K
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K